Medical Advisory Committee
Dr. Stephen Coban
Stephen Couban completed his Bachelor of Science (Honours) in cell and molecular biology at McGill University in 1982 and received his medical degree from Dalhousie University in 1986 (cum laude). After completing a rotating internship at the Queen Elizabeth hospital in Montreal. In 1989, he became a resident in Internal Medicine at Dalhousie and became of Fellow of the Royal College of Physicians and Surgeons (Canada) in 1992. He undertook subspecialty training in hematology at McMaster University (1992-1994) and additional training in blood and marrow transplantation as a Terry Fox Fellow at Princess Margaret Hospital in Toronto (1994-1996).
He is currently Division Head, Hematology in the Department of Medicine at Dalhousie and Director of the Blood and Marrow Transplant Program. He is also co-chair of the Hematology Site Group of the Canadian Clinical Trials Group (CCTG) and represents the CCTG at the North American Leukemia Intergroup.
Dr. Linda Foltz
Foltz completed medical school, internal medicine residency training and hematology subspecialty fellowship at UBC. She joined the Division of Hematology at St. Paul’s Hospital in Vancouver in 2007. She is a Clinical Associate Professor in the UBC Division of Hematology and was Head of the St. Paul’s Hospital Division of Hematology from 2013-2018. Her area of special interest is myeloproliferative neoplasms (MPN). She is a principal investigator for MPN clinical trials and is a founding and executive member of the Canadian MPN Group.
Dr. Shireen Sirhan
Dr. Sirhan is a Hematologist and Medical Oncologist. She is an assistant professor at Mcgill University. Together with Dr. Jaroslav Prchal, she established the first myeloproliferative neoplasms clinic in Canada at the Jewish General Hospital in Montreal.
She completed her medical school, internal medicine and Hematology and Oncology training at McGill University. She further trained in myeloproliferative neoplasms with Dr. Tefferi at the Mayo clinic She also holds a masters degree in Clinical trials from the University of London.
She is founding and executive member of the Canadian MPN Group, and the vice president of research—MPNs for Groupe québécois de recherche en LMC-NMP.
She has authored several publication ins the area of MPN clinical research and has been an investigator on several clinical trials assessing novel agents in the treatment of MPNs.
Dr. Elena Liew
Dr. Elena Liew is an alumna of the University of Alberta medical school and completed her internal medicine there as well. She went on to complete hematology subspecialty training at the University of Calgary and this was followed by a leukemia fellowship at Princess Margaret Hospital in Toronto. Dr. Liew is currently appointed clinical assistant professor in the Division of Hematology at the University of Alberta. Her clinical focus is on myeloid disorders, and she is the local principal investigator for several MPN-related clinical trials.